WallStSmart

Revolution Medicines Inc (RVMD)vsExxon Mobil Corp (XOM)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Exxon Mobil Corp generates 43936290% more annual revenue ($326.01B vs $742,000). XOM leads profitability with a 7.8% profit margin vs 0.0%. XOM earns a higher WallStSmart Score of 50/100 (C-).

RVMD

Avoid

24

out of 100

Grade: F

Growth: 3.7Profit: 3.0Value: 5.0Quality: 7.3
Piotroski: 2/9Altman Z: 3.27

XOM

Buy

50

out of 100

Grade: C-

Growth: 2.7Profit: 5.5Value: 4.7Quality: 6.5
Piotroski: 1/9Altman Z: 3.44
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for RVMD.

XOMSignificantly Overvalued (-34.9%)

Margin of Safety

-34.9%

Fair Value

$107.20

Current Price

$144.57

$37.37 premium

UndervaluedFair: $107.20Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

RVMD1 strengths · Avg: 10.0/10
Altman Z-ScoreHealth
3.2710/10

Safe zone — low bankruptcy risk

XOM5 strengths · Avg: 9.0/10
Market CapQuality
$607.57B10/10

Mega-cap, among the largest globally

Altman Z-ScoreHealth
3.4410/10

Safe zone — low bankruptcy risk

Debt/EquityHealth
0.279/10

Conservative balance sheet, low leverage

Price/BookValuation
2.3x8/10

Reasonable price relative to book value

Free Cash FlowQuality
$2.23B8/10

Generating 2.2B in free cash flow

Areas to Watch

RVMD4 concerns · Avg: 3.5/10
Price/BookValuation
17.1x4/10

Trading at 17.1x book value

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Operating MarginProfitability
0.0%3/10

Operating margin of 0.0%

XOM4 concerns · Avg: 3.0/10
Revenue GrowthGrowth
2.6%4/10

2.6% revenue growth

Profit MarginProfitability
7.8%3/10

7.8% margin — thin

Piotroski F-ScoreQuality
1/93/10

Weak financial health signals

EPS GrowthGrowth
-43.4%2/10

Earnings declined 43.4%

Comparative Analysis Report

WallStSmart Research

Bull Case : RVMD

The strongest argument for RVMD centers on Altman Z-Score.

Bull Case : XOM

The strongest argument for XOM centers on Market Cap, Altman Z-Score, Debt/Equity. PEG of 1.42 suggests the stock is reasonably priced for its growth.

Bear Case : RVMD

The primary concerns for RVMD are Price/Book, EPS Growth, Profit Margin.

Bear Case : XOM

The primary concerns for XOM are Revenue Growth, Profit Margin, Piotroski F-Score.

Key Dynamics to Monitor

RVMD carries more volatility with a beta of 1.41 — expect wider price swings.

XOM is growing revenue faster at 2.6% — sustainability is the question.

XOM generates stronger free cash flow (2.2B), providing more financial flexibility.

Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.

Bottom Line

XOM scores higher overall (50/100 vs 24/100). Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Revolution Medicines Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.

Exxon Mobil Corp

ENERGY · OIL & GAS INTEGRATED · USA

Exxon Mobil Corporation, stylized as ExxonMobil, is an American multinational oil and gas corporation headquartered in Irving, Texas. It is the largest direct descendant of John D. Rockefeller's Standard Oil, and was formed on November 30, 1999 by the merger of Exxon (formerly the Standard Oil Company of New Jersey) and Mobil (formerly the Standard Oil Company of New York). ExxonMobil's primary brands are Exxon, Mobil, Esso, and ExxonMobil Chemical. ExxonMobil is incorporated in New Jersey.

Visit Website →

Want to dig deeper into these stocks?